EUVIMEDEUVIMED entdecken
Crossref

Selective internal radiation therapy for neuroendocrine liver metastases: efficacy, safety and prognostic factors. A retrospective single institution study

D Briol, A Ceratti, R Lhommel, L Annet, C Dragean, E Danse, P Trefois, M Van Den Eynde, A De Cuyper, P Goffette, I Borbath

Acta Gastro Enterologica Belgica · 2025

DOI: 10.51821/88.1.13706 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Gastro Enterologica Belgica, 2025. Verfasst von D Briol und 10 weiteren Autor:innen. Beteiligte Einrichtung: CHU UCL Namur, Saint-Elisabeth, Oncology, Namur, Belgium. Hauptthemen laut MEDLINE: Liver Neoplasms, Neuroendocrine Tumors, Yttrium Radioisotopes, Brachytherapy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and study aims: Selective internal radiation therapy (SIRT) has shown good results in unresectable liver metastases from neuroendocrine neoplasms (NELM) with a high disease control rate (DCR) reported. The aims of the study is to assess retrospectively the efficacy and safety of 10y of SIRT for NELM. Patients and methods: Primary endpoint was objective response rate (ORR) and DCR by RECIST 1.1 at 2, 4 and 12 months (m). Secondary endpoints were overall survival (OS), liver progressionfree survival (liver-PFS), clinical response (NEN-related symptoms improvement) and safety.

Results

50 consecutive patients with NELM who got SIRT from 2011 to 2021 in one center. The two major NEN primary sites were pancreas (46%) and small intestine (36%). Histological NEN grades were 10%, 46% and 44% for grades 1, 2 and 3 respectively. ORR and DCR were 16% and 80% at 2m, 22% and 92% at 4m and 32% and 82% at 12m. Survival rates at 1 and 2 y were 76% and 72% respectively. Prognostic factors for OS and liver-PFS were NEN histological grade (3 vs 1+2) (hazard ratio (HR) for OS: 4.33 [1.8-10.6], for liver-PFS: 3.91 [1.3-11.4]), and early (2m) DCR (HR for OS: 0.14 [0.1-0.4], for liver-PFS: 0.016 [0.003-0.08]). Clinical response occurred in 7 of the 10 symptomatic patients. One patient died from radioembolization-induced liver disease.

Conclusion

SIRT showed efficacy in NELM pts, with a high DCR and an good safety profile. G1-2 grade and early DCR were associated with a better OS and liver-PFS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsNeuroendocrine TumorsYttrium RadioisotopesBrachytherapyHumansMaleFemaleRetrospective StudiesMiddle AgedAgedAdultPrognosisTreatment OutcomePancreatic NeoplasmsAged, 80 and overSurvival Rate

Stichwörter der Autor:innen

SIRTeffectivenessliver metastasesneuroendocrine tumoursoutcomes

Substanzen

Yttrium Radioisotopes

Autor:innen und Institutionen

  • CHU UCL Namur, Saint-Elisabeth, Oncology, Namur, Belgium.
  • Cliniques universitaires Saint-Luc (CUSL), Oncology, Brussels, Belgium.
  • Cliniques universitaires Saint-Luc (CUSL), Nuclear Medicine, Brussels, Belgium.
  • Cliniques universitaires Saint-Luc (CUSL), Radiology, Brussels, Belgium.
  • Cliniques universitaires Saint-Luc (CUSL), Gastroenterology, Brussels, Belgium.

Zitieren

APA

Briol, D., Ceratti, A., Lhommel, R., Annet, L., Dragean, C., Danse, E., Trefois, P., Van Den Eynde, M., De Cuyper, A., Goffette, P., & Borbath, I. (2025). Selective internal radiation therapy for neuroendocrine liver metastases: efficacy, safety and prognostic factors. A retrospective single institution study. Acta Gastro Enterologica Belgica. https://doi.org/10.51821/88.1.13706

Vancouver

Briol D, Ceratti A, Lhommel R, Annet L, Dragean C, Danse E, et al. Selective internal radiation therapy for neuroendocrine liver metastases: efficacy, safety and prognostic factors. A retrospective single institution study. Acta Gastro Enterologica Belgica. 2025. doi:10.51821/88.1.13706

BibTeX
@article{Briol2025,
  author = {Briol, D and Ceratti, A and Lhommel, R and Annet, L and Dragean, C and Danse, E and Trefois, P and Van Den Eynde, M and De Cuyper, A and Goffette, P and Borbath, I},
  title = {Selective internal radiation therapy for neuroendocrine liver metastases: efficacy, safety and prognostic factors. A retrospective single institution study},
  journal = {Acta Gastro Enterologica Belgica},
  year = {2025},
  doi = {10.51821/88.1.13706}
}
Kostenlos starten →